SAVANNAH: Savolitinib plus osimertinib shows high response rates in EGFR-mutant NSCLC with MET overexpression and/or amplification post-osimertinib

Lung, Respiratory and Thoracic Cancer

Do you want to read an article? Please log in or register.

ELCC 2025

Reference

Ahn MJ, Kim TM, Bonanno L, et al. SAVANNAH: Savolitinib + osimertinib in patients with EGFRm advanced NSCLC and MET overexpression and/or amplification following progressive disease on osimertinib. Presented at: European Lung Cancer Congress (ELCC) 2025; 26−29 March 2025. Paris, France. Oral presentation 2O.

Visit the healthbook ELCC 2025 newsroom here.

Reference

Related content

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

MARIPOSA: Amivantamab plus lazertinib reduced the incidence of acquired MET and EGFR resistance alterations versus osimertinib in patients with NSCLC

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC

Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer

LAURA: Improved trend for OS benefit with osimertinib versus placebo in patients with unresectable stage III EGFR-mutant NSCLC

IMROZ: Frontline isatuximab plus VRd followed by isatuximab plus Rd shows significant PFS benefit and deep responses in patients with multiple myeloma

MARIPOSA-2: OS data continued to favor amivantamab plus chemotherapy over chemotherapy alone in patients with EGFR-mutated NSCLC